535 related articles for article (PubMed ID: 25761935)
1. Deregulation of innate immune and inflammatory signaling in myelodysplastic syndromes.
Gañán-Gómez I; Wei Y; Starczynowski DT; Colla S; Yang H; Cabrero-Calvo M; Bohannan ZS; Verma A; Steidl U; Garcia-Manero G
Leukemia; 2015 Jul; 29(7):1458-69. PubMed ID: 25761935
[TBL] [Abstract][Full Text] [Related]
2. Deconstructing innate immune signaling in myelodysplastic syndromes.
Varney ME; Melgar K; Niederkorn M; Smith M; Barreyro L; Starczynowski DT
Exp Hematol; 2015 Aug; 43(8):587-598. PubMed ID: 26143580
[TBL] [Abstract][Full Text] [Related]
3. Innate immune pathways and inflammation in hematopoietic aging, clonal hematopoiesis, and MDS.
Trowbridge JJ; Starczynowski DT
J Exp Med; 2021 Jul; 218(7):. PubMed ID: 34129017
[TBL] [Abstract][Full Text] [Related]
4. The inflammatory microenvironment in MDS.
Yang L; Qian Y; Eksioglu E; Epling-Burnette PK; Wei S
Cell Mol Life Sci; 2015 May; 72(10):1959-66. PubMed ID: 25662443
[TBL] [Abstract][Full Text] [Related]
5. Innate immune signaling in the myelodysplastic syndromes.
Starczynowski DT; Karsan A
Hematol Oncol Clin North Am; 2010 Apr; 24(2):343-59. PubMed ID: 20359630
[TBL] [Abstract][Full Text] [Related]
6. Aging- and Senescence-associated Changes of Mesenchymal Stromal Cells in Myelodysplastic Syndromes.
Mattiucci D; Maurizi G; Leoni P; Poloni A
Cell Transplant; 2018 May; 27(5):754-764. PubMed ID: 29682980
[TBL] [Abstract][Full Text] [Related]
7. Chronic immune response dysregulation in MDS pathogenesis.
Barreyro L; Chlon TM; Starczynowski DT
Blood; 2018 Oct; 132(15):1553-1560. PubMed ID: 30104218
[TBL] [Abstract][Full Text] [Related]
8. Bone marrow niche in the myelodysplastic syndromes.
Cogle CR; Saki N; Khodadi E; Li J; Shahjahani M; Azizidoost S
Leuk Res; 2015 Oct; 39(10):1020-7. PubMed ID: 26276090
[TBL] [Abstract][Full Text] [Related]
9. Disordered Immune Regulation and its Therapeutic Targeting in Myelodysplastic Syndromes.
Ivy KS; Brent Ferrell P
Curr Hematol Malig Rep; 2018 Aug; 13(4):244-255. PubMed ID: 29934935
[TBL] [Abstract][Full Text] [Related]
10. The bone marrow stem stromal imbalance--a key feature of disease progression in case of myelodysplastic mouse model.
Das M; Chatterjee S; Basak P; Das P; Pereira JA; Dutta RK; Chaklader M; Chaudhuri S; Law S
J Stem Cells; 2010; 5(2):49-64. PubMed ID: 22049615
[TBL] [Abstract][Full Text] [Related]
11. Biology of the bone marrow microenvironment and myelodysplastic syndromes.
Rankin EB; Narla A; Park JK; Lin S; Sakamoto KM
Mol Genet Metab; 2015; 116(1-2):24-8. PubMed ID: 26210353
[TBL] [Abstract][Full Text] [Related]
12. KDM6B overexpression activates innate immune signaling and impairs hematopoiesis in mice.
Wei Y; Zheng H; Bao N; Jiang S; Bueso-Ramos CE; Khoury J; Class C; Lu Y; Lin K; Yang H; Ganan-Gomez I; Starczynowski DT; Do KA; Colla S; Garcia-Manero G
Blood Adv; 2018 Oct; 2(19):2491-2504. PubMed ID: 30275007
[TBL] [Abstract][Full Text] [Related]
13. Biologic characteristics of bone marrow mesenchymal stem cells in myelodysplastic syndromes.
Kastrinaki MC; Pontikoglou C; Klaus M; Stavroulaki E; Pavlaki K; Papadaki HA
Curr Stem Cell Res Ther; 2011 Jun; 6(2):122-30. PubMed ID: 20528751
[TBL] [Abstract][Full Text] [Related]
14. Success in bone marrow failure? Novel therapeutic directions based on the immune environment of myelodysplastic syndromes.
Cull AH; Rauh MJ
J Leukoc Biol; 2017 Aug; 102(2):209-219. PubMed ID: 28596252
[TBL] [Abstract][Full Text] [Related]
15. Increased expression of interferon signaling genes in the bone marrow microenvironment of myelodysplastic syndromes.
Kim M; Hwang S; Park K; Kim SY; Lee YK; Lee DS
PLoS One; 2015; 10(3):e0120602. PubMed ID: 25803272
[TBL] [Abstract][Full Text] [Related]
16. Immune dysregulation in myelodysplastic syndrome: Clinical features, pathogenesis and therapeutic strategies.
Wang C; Yang Y; Gao S; Chen J; Yu J; Zhang H; Li M; Zhan X; Li W
Crit Rev Oncol Hematol; 2018 Feb; 122():123-132. PubMed ID: 29458780
[TBL] [Abstract][Full Text] [Related]
17. SOHO State of the Art Update and Next Questions: Biology and Treatment of Myelodysplastic Syndromes.
Sallman DA; Tanaka TN; List A; Bejar R
Clin Lymphoma Myeloma Leuk; 2017 Oct; 17(10):613-620. PubMed ID: 29025689
[TBL] [Abstract][Full Text] [Related]
18. Global H3K4me3 genome mapping reveals alterations of innate immunity signaling and overexpression of JMJD3 in human myelodysplastic syndrome CD34+ cells.
Wei Y; Chen R; Dimicoli S; Bueso-Ramos C; Neuberg D; Pierce S; Wang H; Yang H; Jia Y; Zheng H; Fang Z; Nguyen M; Ganan-Gomez I; Ebert B; Levine R; Kantarjian H; Garcia-Manero G
Leukemia; 2013 Nov; 27(11):2177-86. PubMed ID: 23538751
[TBL] [Abstract][Full Text] [Related]
19. Assessment of stromal function, and its potential contribution to deregulation of hematopoiesis in the myelodysplastic syndromes.
Tauro S; Hepburn MD; Bowen DT; Pippard MJ
Haematologica; 2001 Oct; 86(10):1038-45. PubMed ID: 11602409
[TBL] [Abstract][Full Text] [Related]
20. The central role of inflammatory signaling in the pathogenesis of myelodysplastic syndromes.
Sallman DA; List A
Blood; 2019 Mar; 133(10):1039-1048. PubMed ID: 30670444
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
